ULTIVA® (remifentanil HCl) Plans app for iPhone and iPad

Put Remi* anesthesia plans at your fingertips. This app gives you easy access to plans featuring ULTIVA® (remifentanil HCl) for Injection CII.
• Learn from anesthesia plans for spine, orthopedic, ENT, cardiac, and more.
• Expand your knowledge with a variety of TIVA and balanced anesthesia plans.
• Quickly review Remi dosing guidelines with easy access to a 4-page guide.

THIS APP IS INTENDED ONLY FOR ANESTHESIA PROVIDERS IN THE UNITED STATES. USE OF ANY DRUG, THERAPEUTIC REGIMEN, OR MEDICAL TECHNIQUE MENTIONED IN THIS APP IS SUBJECT TO THE INDEPENDENT KNOWLEDGE AND JUDGMENT OF THE PRACTITIONER.

INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

Indication
ULTIVA is indicated for IV administration:
• As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.
• For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.
• As an analgesic component of monitored anesthesia care in adult patients.

Important Safety Information

WARNING: ADDICTION, ABUSE, AND MISUSE
ULTIVA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing ULTIVA.

Please visit https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dbc63b6e-f8c5-4fd0-8ec3-4f5e19125313 to see the remainder of the Important Safety Information and download the ULTIVA full Prescribing Information, including boxed warning.

If you have questions or comments, please call us at 800.RX.MYLAN.

ULTIVA is a registered trademark of Glaxo Group Limited. The Mylan logo is a registered trademark of Mylan Inc.

*Remifentanil is commonly referred to as Remi by anesthesia providers.